These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 29706123)

  • 1. Pharmacogenomics of blood lipid regulation.
    Legault MA; Tardif JC; Dubé MP
    Pharmacogenomics; 2018 May; 19(7):651-665. PubMed ID: 29706123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of HCAR2 by niacin: benefits beyond lipid lowering.
    Tuteja S
    Pharmacogenomics; 2019 Nov; 20(16):1143-1150. PubMed ID: 31617441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics.
    Gordillo-Marañón M; Zwierzyna M; Charoen P; Drenos F; Chopade S; Shah T; Engmann J; Chaturvedi N; Papacosta O; Wannamethee G; Wong A; Sofat R; Kivimaki M; Price JF; Hughes AD; Gaunt TR; Lawlor DA; Gaulton A; Hingorani AD; Schmidt AF; Finan C
    Nat Commun; 2021 Oct; 12(1):6120. PubMed ID: 34675202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between the
    Zhang QH; Yin RX; Chen WX; Cao XL; Chen YM
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29208769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks.
    Peloso GM; Auer PL; Bis JC; Voorman A; Morrison AC; Stitziel NO; Brody JA; Khetarpal SA; Crosby JR; Fornage M; Isaacs A; Jakobsdottir J; Feitosa MF; Davies G; Huffman JE; Manichaikul A; Davis B; Lohman K; Joon AY; Smith AV; Grove ML; Zanoni P; Redon V; Demissie S; Lawson K; Peters U; Carlson C; Jackson RD; Ryckman KK; Mackey RH; Robinson JG; Siscovick DS; Schreiner PJ; Mychaleckyj JC; Pankow JS; Hofman A; Uitterlinden AG; Harris TB; Taylor KD; Stafford JM; Reynolds LM; Marioni RE; Dehghan A; Franco OH; Patel AP; Lu Y; Hindy G; Gottesman O; Bottinger EP; Melander O; Orho-Melander M; Loos RJ; Duga S; Merlini PA; Farrall M; Goel A; Asselta R; Girelli D; Martinelli N; Shah SH; Kraus WE; Li M; Rader DJ; Reilly MP; McPherson R; Watkins H; Ardissino D; ; Zhang Q; Wang J; Tsai MY; Taylor HA; Correa A; Griswold ME; Lange LA; Starr JM; Rudan I; Eiriksdottir G; Launer LJ; Ordovas JM; Levy D; Chen YD; Reiner AP; Hayward C; Polasek O; Deary IJ; Borecki IB; Liu Y; Gudnason V; Wilson JG; van Duijn CM; Kooperberg C; Rich SS; Psaty BM; Rotter JI; O'Donnell CJ; Rice K; Boerwinkle E; Kathiresan S; Cupples LA
    Am J Hum Genet; 2014 Feb; 94(2):223-32. PubMed ID: 24507774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk scores of common genetic variants for lipid levels influence atherosclerosis and incident coronary heart disease.
    Isaacs A; Willems SM; Bos D; Dehghan A; Hofman A; Ikram MA; Uitterlinden AG; Oostra BA; Franco OH; Witteman JC; van Duijn CM
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2233-9. PubMed ID: 23766260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.
    Kathiresan S; Melander O; Guiducci C; Surti A; Burtt NP; Rieder MJ; Cooper GM; Roos C; Voight BF; Havulinna AS; Wahlstrand B; Hedner T; Corella D; Tai ES; Ordovas JM; Berglund G; Vartiainen E; Jousilahti P; Hedblad B; Taskinen MR; Newton-Cheh C; Salomaa V; Peltonen L; Groop L; Altshuler DM; Orho-Melander M
    Nat Genet; 2008 Feb; 40(2):189-97. PubMed ID: 18193044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
    Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
    Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J; Pernický M; Kiňová S
    Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Chiang CW; Ferrieres J; Foody JM
    Atherosclerosis; 2012 Sep; 224(1):150-3. PubMed ID: 22818564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations.
    Sacks FM;
    Am J Cardiol; 2002 Jul; 90(2):139-43. PubMed ID: 12106843
    [No Abstract]   [Full Text] [Related]  

  • 18. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM; Dorsch MP; Bleske BE
    Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.